<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751422</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1012</org_study_id>
    <secondary_id>NCI-2021-00607</secondary_id>
    <secondary_id>2020-1012</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04751422</nct_id>
  </id_info>
  <brief_title>Medical Data Collection for the Evaluation of Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine</brief_title>
  <official_title>A Single-Center Retrospective Study Evaluating Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study collects data on the use of radiofrequency ablation and cement augmentation for&#xD;
      the treatment of cancer that has spread to the spine (metastases to the spine).&#xD;
      Radiofrequency ablation with cement augmentation is a useful approach for the treatment of&#xD;
      secondary metastasis to the spine. Information collected in this study may help doctors to&#xD;
      learn the effectiveness of this therapy, and may help to evaluate optimal technique,&#xD;
      appropriate patient selection, and management of complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the use of radiofrequency ablation and cement augmentation for the treatment&#xD;
      of secondary metastases to the spine.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients' medical data is collected retrospectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Descriptive statistical analysis will be performed in order to assess technical success, clinical success, and complication rates. Results will be compared with data available from other published literature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical success</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Descriptive statistical analysis will be performed in order to assess technical success, clinical success, and complication rates. Results will be compared with data available from other published literature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rates</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Descriptive statistical analysis will be performed in order to assess technical success, clinical success, and complication rates. Results will be compared with data available from other published literature.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Spine</condition>
  <arm_group>
    <arm_group_label>Observational (data collection)</arm_group_label>
    <description>Patients' medical data is collected retrospectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Medical data is collected</description>
    <arm_group_label>Observational (data collection)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent radiofrequency ablation with cement augmentation at the Department&#xD;
        of Interventional Radiology at MD Anderson Cancer Center (MDACC) between 1/1/2017 and&#xD;
        9/26/2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent radiofrequency ablation with cement augmentation at the&#xD;
             Department of Interventional Radiology at MD Anderson Cancer Center (MDACC) between&#xD;
             1/1/2017 and 9/26/2020&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul A Sheth</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul A. Sheth</last_name>
      <phone>713-745-0652</phone>
      <email>rasheth@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Rahul A. Sheth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

